Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease

NCT00389376 is registered in ClinicalTrials.gov with National Center for Complementary and Integrative Health (NCCIH) as lead sponsor.

NCT NCT00389376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00389376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single and Multiple Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Administered Silymarin (Legalon) in Non-Cirrhotic Subjects With Chronic Hepatitis C or Non-Alcoholic Fatty Liver Disease
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2006
Completion date
February 29, 2008
Enrollment
56 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, non-alcoholic fatty liver disease